Nascent Biotech Inc. [NBIO]

Source: 

Company Overview

Nascent Biotech Inc. is actively developing its primary asset, Pritumumab, for the treatment of brain cancer and pancreatic cancer.  Nascent is also actively researching other cancers that have a high probability of benefiting from the therapeutic effects of Pritumumab because they share a common molecular target.